St John’s Wort vs Saffron vs SSRIs for Depression: What Independent Evidence Shows

St John's wort, saffron and SSRIs are the three options people most often weigh against each other for low mood. They are not equals. SSRIs are prescription medicines with regulator-held trial data. St John's wort is a licensed prescription drug in Germany but an unregulated supplement in the US. Saffron is a spice with a small, mostly single-country trial base. This comparison sets out the efficacy, pros, cons, interactions, dosage and side effects of each. It also shows who paid for the evidence, so you can see how much each conclusion depends on the people selling the product.

Table of contents

• Evidence summary
• What we compared, and how
• Side-by-side comparison
• St John's wort: pros, cons, dosage, side effects
• Saffron: pros, cons, dosage, side effects
• Saffron supplements: the branded-extract evidence
• SSRIs: pros, cons, dosage, side effects
• Head-to-head evidence
• All interactions
• Dosage compared
• Side effects compared
• Who should avoid which
• Follow the money: who paid for the evidence
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

What we compared, and how

This article covers adults with depressive symptoms, from sub-clinical low mood to diagnosed major depression, and separates mild-to-moderate from severe illness wherever the data allow. It compares:

• St John's wort (Hypericum perforatum), mainly the standardized extracts used in trials: WS 5570/5572 (Dr. Willmar Schwabe), LI 160, Ze 117 (Max Zeller Söhne) and STW3/STW3-VI (Steigerwald, now Bayer).
• Saffron (Crocus sativus) stigma extracts, including the branded supplement ingredients sold today: affron, Safr'Inside, Satiereal, Moodreal and others.
• SSRIs as a class, with drug-specific notes for sertraline, escitalopram, citalopram, fluoxetine, paroxetine and fluvoxamine.

For every key source we checked who paid for it and what the authors disclosed, following our evidence methods. Findings funded by a company that sells the product are labeled [SELLER-FUNDED]; findings funded by a competitor are labeled [COMPETITOR-FUNDED]. Neither is presented as settled fact.

Side-by-side comparison

St John's wort: pros, cons, dosage, side effects

St John's wort is covered in depth in our St John's wort evidence review. The summary below focuses on how it compares.

Efficacy

In mild-to-moderate depression, the Cochrane review found standardized extracts better than placebo (RR 1.28 in the larger trials, 1.87 in the smaller ones) and about as effective as standard antidepressants, including SSRIs (RR 1.00, 95% CI 0.90–1.11), with fewer dropouts from side effects (OR 0.53) (Linde et al., 2008). The same review found that "trials from German-speaking countries reported findings more favourable to hypericum", and it could not rule out small, flawed trials as the reason.

In moderately severe depression the picture is contested. The NIH-funded Hypericum Depression Trial Study Group trial (n = 340) found full response in 23.9% on St John's wort, 24.8% on sertraline and 31.9% on placebo. Neither drug beat placebo (HDTSG, JAMA 2002). A trial funded by Pfizer, which sells sertraline, was null on its primary outcome [COMPETITOR-FUNDED] (Shelton et al., JAMA 2001). A trial funded by Dr. Willmar Schwabe, which sells WS 5570, found the extract non-inferior and statistically superior to paroxetine [SELLER-FUNDED] (Szegedi et al., BMJ 2005).

Pros

• About half the side-effect dropouts of SSRIs in pooled trials, though part of this advantage comes from trials using paroxetine, one of the worse-tolerated SSRIs, as the comparator.
• Licensed, standardized prescription extracts exist in Germany, with pharmaceutical-grade quality control.
• No established withdrawal syndrome.

Cons

• Serious drug interactions (see all interactions).
• Potency varies widely between products. NICE cites "the different potencies of the preparations available", and Cochrane's results apply only to the extracts tested (NICE NG222).
• Evidence is skewed by country and funder, and there is little evidence in severe depression.
• In the US it is sold under DSHEA without FDA pre-market approval (NCCIH).

Interactions

Hyperforin activates the pregnane X receptor, which induces CYP3A4, CYP2C9, CYP2C19 and P-glycoprotein. This lowers blood levels of many drugs, including oral contraceptives, warfarin, cyclosporine, tacrolimus, digoxin, HIV antiretrovirals, some chemotherapy and methadone. Separately, its serotonergic activity creates a risk of serotonin syndrome with SSRIs, SNRIs, triptans, tramadol, MAOIs and linezolid (NCCIH).

A 20-volunteer study of the low-hyperforin extract Ze 117 found no clinically relevant effect on CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP3A4 or P-glycoprotein [SELLER-FUNDED: Max Zeller Söhne] (Zahner et al., 2019). The University of Liverpool interaction service independently allows that co-administration "may be considered" with products stating under 1 mg/day hyperforin (Liverpool HEP). This does not remove the serotonin risk with SSRIs.

Dosage

• Typical: 900 mg/day of an extract standardized to 0.12–0.28% hypericin (300 mg three times daily). Trial range 500–1,800 mg/day. Ze 117 is used at 500 mg/day.
• Onset: up to about 4 weeks (healthdirect Australia).
• Stopping: there is no formal taper guidance. When stopping while on interacting drugs, their levels rise as enzyme induction wears off over roughly 1–2 weeks, so drugs such as warfarin, cyclosporine or methadone need monitoring.

Side effects

• Common: GI upset, dizziness, restlessness, fatigue, dry mouth, photosensitivity.
• Serious: mania or hypomania in bipolar-spectrum patients; serotonin syndrome if combined with serotonergic drugs.

Regulatory status

• Germany: prescription-only for moderate depression since 1 April 2009; products for mild depressive mood remain over the counter (ABDA).
• Ireland: prescription-only since 2000 (IrishHealthPro).
• UK: NICE says it "may be of benefit in less severe depression" but advises clinicians not to prescribe or advise it (NICE NG222).
• France: listed among plants permitted in food supplements (DGCCRF list, 2019).

Saffron: pros, cons, dosage, side effects

Our full saffron for depression review covers mechanisms, forms and every claimed benefit. Here we focus on the comparison and on the supplements people actually buy.

Efficacy

The largest synthesis, a GRADE meta-analysis of 34 RCTs with 1,769 participants, found moderate-certainty improvement on self-rated depression and anxiety scales, but no significant effect on clinician-rated depression or anxiety. The authors concluded that the lack of clinician-rated effects "underscores need for high-quality trials" (Mahmoudi et al., 2026).

Earlier meta-analyses reported large effects but flagged the same weakness. Hausenblas et al. called for "larger clinical trials, conducted by research teams outside of Iran" (Hausenblas, 2013). Tóth et al. noted that "all the included trials were performed in Iran" and that overlapping authors could shape results (Tóth et al., Planta Med 2019).

There is essentially no evidence in severe depression, and no trial has lasted longer than 12 weeks.

Pros

• Few side effects reported in trials, fewer than with SSRIs.
• No enzyme-induction interactions of the kind that make St John's wort risky.
• Consistent, if small, self-rated benefit across many trials.

Cons

• Evidence comes almost entirely from Iran, the world's dominant saffron producer, and from overlapping research teams.
• Clinician-rated benefit is not shown in the largest meta-analysis.
• All non-Iranian supplement trials are seller-funded or seller-co-authored (see below).
• The raw spice is widely adulterated, and supplement labels are often inaccurate.
• Expensive per trial-equivalent dose.

Interactions

Interactions are mostly theoretical: possible additive effects with anticoagulants and antiplatelets, antihypertensives, antidiabetic drugs and sedatives, and a theoretical serotonergic overlap. The clearest human signal is a case report of bleeding in a man taking rivaroxaban after he added a saffron supplement; it resolved when saffron was stopped, and the authors advised avoiding the combination (case report, 2022). In an add-on trial, adults already on antidepressants took affron 28 mg/day without a signal of serotonin toxicity, but the trial was too small to detect rare events [SELLER-FUNDED] (Lopresti et al., 2019).

Dosage

• Most trials: 30 mg/day of stigma extract (15 mg twice daily). affron: 28 mg/day (14 mg twice daily). Safr'Inside: 20–30 mg/day.
• Trial durations: 6–12 weeks. Judge any effect at 8–12 weeks.
• Toxic effects have been reported at 5 g doses, about 170 times the trial dose, so bulk-spice self-dosing is inadvisable (Drugs.com).
• No withdrawal syndrome has been described.

Side effects

• Reported: mild GI upset, nausea, appetite change, headache, anxiety or sedation.
• Bleeding risk with anticoagulants (see above).
• Pregnancy: high doses have uterine-stimulant effects; there are no safety data at supplement doses. Avoid.
• Hypomania is a theoretical risk; we found no verified case report at supplement doses.

Saffron supplements: the branded-extract evidence

Most saffron trials behind the headline meta-analyses used saffron of undefined composition donated to Iranian universities by Mashhad saffron companies. The 2004 imipramine trial, for example, used saffron "dedicated by Novin Zaferan Co (Mashhad, Iran)" (Akhondzadeh et al., 2004). The products on shelves today are different: branded, standardized extracts whose trials were mostly run in Australia, the UK, France and India. Every one of those trials we found was funded, supplied or co-authored by the company selling the extract.

Product by product

None of these extracts has been tested in a trial independent of its seller.

Trial by trial

Does the capsule contain what was trialed?

In independent testing of six US saffron supplements, ConsumerLab found amounts of safranal, picrocrocin and crocins varying "more than 50-fold on some measures", and only 4 of 6 products could be fully approved. It warned that label claims appear to rely on a testing method that "can vastly overestimate actual amounts" (ConsumerLab, 2023). A Spanish survey of 17 retail supplements found that declared content did not match in 65% of cases; one of its co-authors works for Pharmactive, which makes a competing product, so treat it as supportive rather than independent (Mena-García et al., 2023).

Labels also mislead because of method. The standard ISO 3632 UV method overestimates safranal, because other saffron compounds absorb at the same wavelength. A label reading "2% safranal" measured by UV and one reading "0.2% safranal" measured by HPLC can describe similar material. A high UV safranal number is not a quality signal.

Marketing claims vs what the trials showed

Regulators have not endorsed saffron for mood. In 2021 the FDA warned Saffron Health Sciences that depression and Alzheimer's claims for its Crocin Rich products made them unapproved new drugs (FDA warning letter, 2021). The WFSBP/CANMAT 2022 guideline gave saffron only a provisional recommendation for depression, below St John's wort (Sarris et al., 2022).

If you choose a saffron supplement

• Choose a product that names a trialed extract and gives its dose, for example affron 28 mg/day or Safr'Inside 30 mg/day. "Saffron 88.5 mg" of an unnamed extract cannot be linked to any trial.
• Look for a certificate of analysis reporting crocins, picrocrocin and safranal by HPLC, or third-party testing. Treat UV-based safranal claims as uninformative.
• Compare price per trial-equivalent daily dose, not per capsule.
• Judge it at 8–12 weeks and stop if there is no clear benefit.
• Do not use it instead of treatment for diagnosed or moderate-to-severe depression.

SSRIs: pros, cons, dosage, side effects

For each SSRI in more depth, see our reviews of sertraline, escitalopram, citalopram, fluoxetine, paroxetine and fluvoxamine.

Efficacy

A network meta-analysis of 522 trials and 116,477 participants found all 21 antidepressants studied better than placebo (Cipriani et al., Lancet 2018). It was publicly funded, but most underlying trials were run by manufacturers and only 18% were rated at low risk of bias. The cleaner FDA data show a real but modest effect, concentrated in a minority and in more severe illness (Stone et al., 2022; Fournier et al., 2010).

A 2022 review challenged the idea that depression is caused by low serotonin (Moncrieff et al., 2022). That is a question about how SSRIs work, not evidence that they do not work.

Pros

• The largest evidence base, including complete regulator-held datasets.
• Proven in moderate-to-severe depression and in relapse prevention.
• Cheap, generic and made to regulated manufacturing standards.
• Established dosing, monitoring and tapering protocols.

Cons

• Small average benefit over placebo in milder illness.
• Sexual dysfunction, emotional blunting and discontinuation symptoms.
• FDA boxed warning for suicidality in people under 25.
• A history of manufacturer misconduct distorts the evidence. The 2015 reanalysis of paroxetine Study 329 found no benefit and more harm in adolescents (Le Noury et al., BMJ 2015). GSK paid $3 billion in 2012, including for misbranding Paxil for under-18s (US DOJ), and Forest paid more than $313 million in 2010 over Celexa and Lexapro promotion (US DOJ).

Interactions

• Serotonin syndrome: MAOIs (washout required; 5 weeks after fluoxetine), linezolid, methylene blue, St John's wort, tramadol, triptans.
• Bleeding: NSAIDs, aspirin, anticoagulants.
• CYP2D6 inhibition by fluoxetine and paroxetine: reduced tamoxifen activation and codeine effect; raised metoprolol levels.
• CYP1A2 inhibition by fluvoxamine: clozapine, theophylline, caffeine; tizanidine is contraindicated.
• CYP2C19 inhibitors (omeprazole, cimetidine) raise citalopram and escitalopram levels and QT risk.

Dosage

See the dosage table. SSRIs take 2–6 weeks to start working and 6–8 weeks or longer for full effect. Guidelines advise continuing for at least 6 months after remission. Stopping should be gradual and supervised.

Side effects

• Common: nausea and other GI effects, sexual dysfunction, insomnia or drowsiness, weight change, emotional blunting.
• Serious: hyponatremia (especially in older adults), bleeding, falls, QT prolongation (citalopram), serotonin syndrome.
• Withdrawal: a 2024 meta-analysis of 79 studies found symptoms in 31% after stopping antidepressants vs 17% after stopping placebo, a net rate of about 15%, with about 1 in 35 severe (Henssler et al., Lancet Psychiatry 2024; authors declared no competing interests). An earlier review estimated 56% (Davies & Read, 2019). The true figure is disputed, and long-term users were under-represented in the trials behind the lower estimate.
• Persistent sexual dysfunction: since 2019 the EMA has required SSRI labels to state that sexual dysfunction can continue after stopping (EMA PRAC, 2019). Australia's TGA calls it rare but likely under-reported (TGA).

Head-to-head evidence

All interactions

Sources: NCCIH, Liverpool HEP, FDA citalopram safety communication, saffron–rivaroxaban case report. Absence of a reported interaction is a gap in the evidence, not proof of safety.

Dosage compared

SSRI doses are labeled doses; always follow your national label and prescriber. This table is for information, not personal dosing advice.

Side effects compared

Who should avoid which

• Anyone on another serotonergic drug should not take St John's wort.
• Anyone on contraceptives, anticoagulants, transplant drugs, HIV drugs or chemotherapy should not start or stop St John's wort without their prescriber.
• Pregnancy and breastfeeding: SSRIs have the most safety data (sertraline is often preferred; paroxetine is usually avoided). St John's wort and medicinal-dose saffron lack adequate data; avoid.
• Bipolar disorder: all three can trigger mania. Get specialist advice first.
• Under 25: SSRIs carry an FDA boxed warning for suicidality. NICE advises against St John's wort for children and young people. The only adolescent saffron trial is seller-funded.
• Older adults: SSRIs raise the risk of hyponatremia, falls and bleeding; St John's wort interaction risk rises with the number of medicines taken.
• Severe depression or thoughts of suicide: seek professional care promptly. Neither herb has been tested in severe illness.

Follow the money: who paid for the evidence

Related research

For each option in more depth, see our St John's wort evidence review and saffron for depression review. For individual SSRIs, see sertraline, escitalopram, citalopram, fluoxetine, paroxetine and fluvoxamine. For the wider picture, see Stress, anxiety & depression: supplement evidence and the Stress, anxiety & depression prevention guide.

This article will be revisited as new evidence emerges, particularly any independently funded, non-Iranian trial of a branded saffron extract.

Frequently asked questions

Sources and funding notes

Every claim in this article is traced to a specific source below, with funding and conflicts of interest checked for each. Benefit claims rest on Independent or Probably independent sources. Seller-funded and competitor-funded sources are included so readers can see what the manufacturers' own evidence shows, and are labeled as such. Credibility grades run from A (regulator-held or complete data, no commercial ties) to D (funded, designed or co-authored by a seller or competitor).

What we could not verify

• The funding statements for the 2026 affron trial and the 2025 Safr'Inside insomnia trial. Both are treated as seller-linked until confirmed.
• Funding and conflicts for the Rahimi 2009, Ng 2017, Hausenblas 2013 and Shafiee 2025 meta-analyses.
• Whether any registered trial outcomes differ from the published ones; registration numbers are listed so readers can check.
• Two newer saffron trials whose extract and funder we could not identify (a 2025 Italian anhedonia pilot and a 2026 Indonesian student trial). Either could become the first independent replication.
• St John's wort and saffron regulatory status in India and the UAE.